NCT04375267 2026-04-14
LuPARP
Vastra Gotaland Region
Phase 1 Completed
Clinical Trials
7 trialsNCT06130254 2026-04-09
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT03923270 2026-04-01
Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
NCT04550104 2025-12-19
CONCORDE
University of Leeds
Phase 1 Recruiting
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT03532880 2025-02-07
A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02511795 2019-11-07
AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors
AstraZeneca
Phase 1 Completed